Antibiotics

Antibiotics
Mupirocin [HOT]
4-AA [Intermediate] [HOT]

 

 

Mupirocin calcium dihydrate,115074-43-6
Mupirocin calcium dihydrate
Mupirocin calcium dihydrate,115074-43-6
CAS
115074-43-6
Molecular Formula
C52H86CaO18.2H2O
Molecular Weight
1075.34
Systematic Name
Nonanoic acid, 9-((3-methyl-1-oxo-4-(tetrahydro-3,4-dihydroxy-5-((3-(2-hydroxy-1-methylpropyl)oxiranyl)-methyl)-2H-pyran-2-yl)-2-butenyl)oxy)-, calcium salt (2:1), dihydrate, (2S-(2alpha(E),3beta,4beta,5alpha(2R*,3R* (1R*,2R*))))
Standard
EPVII
Certificate of analysis
Mupirocin calcium dihydrate,115074-43-6
View via PDF file
Mupirocin calcium dihydrate,115074-43-6
Specification
Items
Specification
Test result
Appearance
A white or almost white powder
Complies
Identification
Examine by IR, Positive
Complies
Water
3.0-4.5%
3.3%
Chloride
Not more than 0.5%
Complies
Not more than 0.5%
Not more than 20ppm
Complies
Specific optical rotation
-16° - -20°
-19°
Total impurities
Not more than 4.5%
4.4%
Max impurity
Not more than 2.5%
1.4%
Any other individual
Not more than 1.0%
Complies
Assay(Dried basis)
93.0-100.5%
95.0%
Contact us for more information
Chemical information
Compound Name*
CAS No. "N/A" if the CAS not available*
Quantity*
Contact information
Contact person*
Email Address *
Tel No.*
Company or Organization Name*
Shipping Address*
Country
Remarks

<Privacy policy: the contact information will be only used for this business contact>

Related Antibiotics
Mupirocin [HOT]
4-AA [Intermediate]
 
Patent Disclaimer
PD1
Products protected by valid patents are not offered for sale in jurisdictions where the sale of such products constitutes a patent infringement. The current list only reflects the products and technologies that are available, under development: note that some products may be developed or produced for internal and experimental uses with no commercal aim.
PD2
Sales of products are limited to those allowed by Chapter VII PLPRC 63, the above includes Research and development quantities.
PD3
the buyer assumes responsibility of all patent considerations in the use of
Lano ’s Pharmaceutical Co.,Ltd product(Mupirocin calcium dihydrate,115074-43-6).
PD4
R&D use in accordance with (1) 35 USC 271(e)+A13(1) in the U.S.; (2) Section 69.1 of Japanese Patent Law in Japan; (3) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (4) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (5) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (6) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (7) such similar laws and rules as may apply in various other countries.